1. Optimizing Patient Outcomes in IBD

3. Introduction

4. Pathophysiology of IBD

5. Early Treatment During the Window of Opportunity Could Halt Disease Progression

6. Benefits and Limitations of Anti-TNF Agents

7. Access to New Biologics for Early Treatment of IBD

8. Approved Biologics in IBD: Different MOA

9. Distinct MOA of New Biologics Translates Into Clinical Outcomes

10. Clinical Trials Outcomes: Conventional vs New Biologics

11. Considerations for Selecting a Biologic for an Individual Patient

12. Considerations for Selecting a Biologic for an Individual Patient (cont)

13. Vedolizumab Real-World Evidence: US VICTORY Consortium

14. Vedolizumab Real-World Effectiveness: Meta-Analysis

15. Mucosal Healing With Conventional Anti-TNF Agents in CD

16. Mucosal Healing With New Biologics: Vedolizumab

17. Mucosal Healing With New Biologics: Ustekinumab

18. Avoiding Complications, Fistula, Surgery, and Hospitalization in CD: Conventional Biologics

19. Avoiding Complications, Fistula, Surgery, and Hospitalization in CD: New Biologics

20. Targeting the Right Drug to the Individual Patient at the Right Time

21. Emerging Therapies

22. Conclusions